Alaunos Therapeutics, Inc.
TCRT
$4.29
$0.2947.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 100.00% | 300.00% | -- | 0.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 100.00% | 300.00% | -- | 0.00% | -- |
| Cost of Revenue | -81.82% | -109.22% | -96.09% | -96.53% | -99.83% |
| Gross Profit | 100.00% | 109.66% | 96.09% | 96.60% | 99.85% |
| SG&A Expenses | -53.80% | -65.20% | -71.86% | -67.49% | -48.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.23% | -77.42% | -84.10% | -85.79% | -81.98% |
| Operating Income | 37.31% | 77.53% | 84.10% | 85.83% | 81.99% |
| Income Before Tax | 36.21% | 90.54% | 86.70% | 87.13% | 83.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.21% | 90.54% | 86.70% | 87.13% | 83.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.21% | 90.54% | 86.70% | 87.13% | 83.26% |
| EBIT | 37.31% | 77.53% | 84.10% | 85.83% | 81.99% |
| EBITDA | 37.27% | 75.81% | 82.46% | 84.52% | 80.61% |
| EPS Basic | 36.21% | 90.54% | 86.71% | 87.15% | 83.30% |
| Normalized Basic EPS | 36.21% | 77.20% | 84.01% | 87.50% | 83.30% |
| EPS Diluted | 36.21% | 90.54% | 86.71% | 87.15% | 83.30% |
| Normalized Diluted EPS | 36.21% | 77.20% | 84.01% | 87.50% | 83.30% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.06% | 0.16% | 0.21% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.06% | 0.16% | 0.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |